Report
Onward Medical FIRST LOOK: First commercial sales for ARC-EX
Only days after its de novo FDA approval for ARC-EX in clinic use, Onward has realized its first sales of the device. The two initial customers are UW Medicine and Next Steps Chicago, which appears in line with the company's previously communicated limited launch strategy. We look forward to seeing more sales materialize over the year. We reiterate our € 10.4 TP and Buy rating.
Underlying
ONWARD MEDICAL NV
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.